Tesla executives almost never say a word about the $TSLA plant in Buffalo in their earnings letter or conference call. But they had a few words about Buffalo this quarter. https://t.co/xVAGTbT0Xc
If you remember going to the AM&A's store downtown, you won't believe what @jepsteinbuffalo saw when he got a tour of what it's like now. https://t.co/uSfpJL3tvf via @TheBuffaloNews
Who'd have ever thought Buffalo Niagara would be a good place to flip a house? My, how times have changed. Here's why flippers can make good money here. https://t.co/IdKGf6Txxn via @TheBuffaloNews
Four of the top 12 towns with the most competitive housing markets in the US are in the Buffalo Niagara region, according to Redfin. https://t.co/5AAdih5A2X
November's hiring binge didn't carry over into December, but that's OK. The important thing is that hiring didn't regress last month. https://t.co/9qK9gqnxqr
Four of the top 12 towns with the most competitive housing markets in the US are in the Buffalo Niagara region, according to Redfin. https://t.co/5AAdih5A2X
Washington state learned a sharp lesson about concentration risk. When a tax system leans heavily on a few individuals, the exit door matters just as much as the tax rate. https://t.co/X9C0qKyPVC
Lee Enterprises to raise $50 million in deal led by billionaire David Hoffmann that also shakes up management. $LEE https://t.co/kUSeKRjBXm via @TheBuffaloNews
New York, which wants to add more nuclear power, struck a deal with Ontario to work together to develop nuclear technology https://t.co/5RtxFxmtBK via @TheBuffaloNews
Novo just cut self-pay price of Ozempic to $349, down 65% from launch. It stands out bc most drugs get pricier over time and shows the effect when patients, rather than third parties, see costs directly. Patients having more skin in the game is a way to lower healthcare costs.
Drugmakers typically launch new products at a βmodestly highβ price, desiring to avoid insurer resistance and encourage broad patient uptake. Once doctors and patients adopt the drug, manufacturers often hike prices annually (often 9.9%) knowing that payors lose leverage once the drug is entrenched in clinical practice.
GLP-1s broke this pattern. When insurers balked at launch prices of $1,000β$1,300 per month, many patients were forced to pay entirely out of pocket. This limited uptake. In response, Lilly and Novo Nordisk have slashed prices over time, particularly for cash-paying customers.
Third-party payors are a necessary part of the healthcare systemβthatβs the core function of insurance. However, this same system also plays a major role in driving up the cost of drugs. Finding the right balance can lower costs without decreasing access.